Pedro Antonio Cascales Campos-rekin lankidetzan egindako argitalpenak (7)

2023

  1. HIPEC in Ovarian Cancer Is the Future… and Always Will Be? Results from a Spanish Multicentric Survey

    Cancers, Vol. 15, Núm. 13

2022

  1. Interval cytoredutive surgery and HIPEC in advanced ovarian cancer with small-bowel disease: results and reflections

    Clinical and Translational Oncology, Vol. 24, Núm. 8, pp. 1542-1548

2021

  1. Acute renal disease in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and HIPEC: the influence of surgery and the cytostatic agent used

    Langenbeck's Archives of Surgery, Vol. 406, Núm. 7, pp. 2449-2456

  2. Urinary and fecal incontinence in patients with advanced ovarian cancer treated with CRS + HIPEC

    Surgical Oncology, Vol. 36, pp. 115-119

2020

  1. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 852-859

  2. Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies

    Hernia, Vol. 24, Núm. 2, pp. 257-263

2019

  1. Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

    Clinical and Experimental Metastasis, Vol. 36, Núm. 5, pp. 433-439